Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282839478> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W4282839478 endingPage "987" @default.
- W4282839478 startingPage "987" @default.
- W4282839478 abstract "Nicotinamide adenine dinucleotide (NAD+) coenzymes are the central regulators of cellular metabolism. While the NAD + system is dysregulated by metabolic stress and age-related conditions, nicotinamide riboside (NR) augments NAD + levels and may contribute to the reduction of inflammation. As advancing age is often accompanied by chronically elevated inflammation (i.e., ‘inflammaging’), targeting chronic inflammation may be a viable strategy to preserve aspects of health and function. The objective of this study was to investigate the clinical evidence of NR’s mitigation of inflammation in humans. We systematically evaluated peer-reviewed, published clinical trials of oral NR supplementation that included analysis of inflammatory markers. There were no restrictions for age, sex, health status, or use of other bioactives. Key study details were assessed to compare experimental designs and results. We identified 5 clinical trials of oral NR supplementation that measured inflammation. There was substantial heterogeneity in inflammatory endpoints evaluated. NR dose and treatment duration ranged from 1–2 g/day and 5-d– 6-wks, respectively. Participants varied in age (18–78 years) and health status. In one study, NR was given as part of a nutritional cocktail, while NR was the sole intervention in the remaining studies. Of the 3 studies assessing circulating inflammatory markers, two investigated IL-6 and reported significant reductions in its levels with NR treatment, while effects on MCP-1 and TNF-α were inconsistent. NR significantly lowered gene expression of IL-6 and IL-18, but not NLRP3 or IL-1B in peripheral blood mononuclear cells in one study. Another study documented significant reductions in the gene expression of IFNB and CXCL10, but no change to TNFA expression, in the monocytes of the NR-treated group. Moreover, NR treatment led to lower concentrations of IFNβ, but not TNF-α, in monocytes. Preliminary evidence suggests that NR may improve some inflammatory measures, with potential for more robust effects among populations with compromised NAD + and higher inflammation status, e.g., elderly or diseased. More work is needed to clarify which inflammatory markers are targeted by NR, and the extent to which they are further modified by dose and participant demographics. N/A." @default.
- W4282839478 created "2022-06-15" @default.
- W4282839478 creator A5019584165 @default.
- W4282839478 creator A5046519059 @default.
- W4282839478 creator A5065809687 @default.
- W4282839478 creator A5079718238 @default.
- W4282839478 creator A5087144634 @default.
- W4282839478 creator A5091315318 @default.
- W4282839478 date "2022-06-01" @default.
- W4282839478 modified "2023-10-01" @default.
- W4282839478 title "The Clinical Effects of Nicotinamide Riboside on Inflammatory Parameters" @default.
- W4282839478 doi "https://doi.org/10.1093/cdn/nzac068.016" @default.
- W4282839478 hasPublicationYear "2022" @default.
- W4282839478 type Work @default.
- W4282839478 citedByCount "1" @default.
- W4282839478 countsByYear W42828394782023 @default.
- W4282839478 crossrefType "journal-article" @default.
- W4282839478 hasAuthorship W4282839478A5019584165 @default.
- W4282839478 hasAuthorship W4282839478A5046519059 @default.
- W4282839478 hasAuthorship W4282839478A5065809687 @default.
- W4282839478 hasAuthorship W4282839478A5079718238 @default.
- W4282839478 hasAuthorship W4282839478A5087144634 @default.
- W4282839478 hasAuthorship W4282839478A5091315318 @default.
- W4282839478 hasBestOaLocation W42828394781 @default.
- W4282839478 hasConcept C126322002 @default.
- W4282839478 hasConcept C137061746 @default.
- W4282839478 hasConcept C181199279 @default.
- W4282839478 hasConcept C202751555 @default.
- W4282839478 hasConcept C203014093 @default.
- W4282839478 hasConcept C2776901170 @default.
- W4282839478 hasConcept C2776914184 @default.
- W4282839478 hasConcept C2779728014 @default.
- W4282839478 hasConcept C2780561631 @default.
- W4282839478 hasConcept C42407357 @default.
- W4282839478 hasConcept C535046627 @default.
- W4282839478 hasConcept C55493867 @default.
- W4282839478 hasConcept C71924100 @default.
- W4282839478 hasConcept C75520062 @default.
- W4282839478 hasConcept C86803240 @default.
- W4282839478 hasConceptScore W4282839478C126322002 @default.
- W4282839478 hasConceptScore W4282839478C137061746 @default.
- W4282839478 hasConceptScore W4282839478C181199279 @default.
- W4282839478 hasConceptScore W4282839478C202751555 @default.
- W4282839478 hasConceptScore W4282839478C203014093 @default.
- W4282839478 hasConceptScore W4282839478C2776901170 @default.
- W4282839478 hasConceptScore W4282839478C2776914184 @default.
- W4282839478 hasConceptScore W4282839478C2779728014 @default.
- W4282839478 hasConceptScore W4282839478C2780561631 @default.
- W4282839478 hasConceptScore W4282839478C42407357 @default.
- W4282839478 hasConceptScore W4282839478C535046627 @default.
- W4282839478 hasConceptScore W4282839478C55493867 @default.
- W4282839478 hasConceptScore W4282839478C71924100 @default.
- W4282839478 hasConceptScore W4282839478C75520062 @default.
- W4282839478 hasConceptScore W4282839478C86803240 @default.
- W4282839478 hasLocation W42828394781 @default.
- W4282839478 hasLocation W42828394782 @default.
- W4282839478 hasOpenAccess W4282839478 @default.
- W4282839478 hasPrimaryLocation W42828394781 @default.
- W4282839478 hasRelatedWork W1990022835 @default.
- W4282839478 hasRelatedWork W2023871611 @default.
- W4282839478 hasRelatedWork W2030955780 @default.
- W4282839478 hasRelatedWork W2127483170 @default.
- W4282839478 hasRelatedWork W2140699690 @default.
- W4282839478 hasRelatedWork W2334550510 @default.
- W4282839478 hasRelatedWork W2605539210 @default.
- W4282839478 hasRelatedWork W2988259787 @default.
- W4282839478 hasRelatedWork W3159973018 @default.
- W4282839478 hasRelatedWork W3206129490 @default.
- W4282839478 hasVolume "6" @default.
- W4282839478 isParatext "false" @default.
- W4282839478 isRetracted "false" @default.
- W4282839478 workType "article" @default.